View in EDS HTML Full Text PDF Full Text

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.

Saved in:
Bibliographic Details
Title: CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Authors: Chen Y; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Huang Y; Fujian Medical University Cancer Hospital, Fuzhou, China., Gao X; Geneplus-Beijing, Beijing, China., Li Y; Fujian Medical University Cancer Hospital, Fuzhou, China., Lin J; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Chen L; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Chang L; Geneplus-Beijing, Beijing, China., Chen G; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Pathology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China., Guan Y; Geneplus-Beijing, Beijing, China., Pan LK; CCIC Group, Kuok Kim (Macao) Medical Center III, Macao, China.; Hui Xian Medical Center, Macao, China., Xia X; Geneplus-Beijing, Beijing, China., Guo Z; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Pan J; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China., Xu Y; Geneplus-Beijing, Beijing, China., Yi X; Geneplus-Beijing, Beijing, China., Chen C; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.
Source: Frontiers in immunology [Front Immunol] 2020 Aug 10; Vol. 11, pp. 1620. Date of Electronic Publication: 2020 Aug 10 (Print Publication: 2020).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32903763
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Huang+Y%22">Huang Y</searchLink>; Fujian Medical University Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Gao+X%22">Gao X</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Fujian Medical University Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Lin+J%22">Lin J</searchLink>; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Chen+L%22">Chen L</searchLink>; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Chang+L%22">Chang L</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Chen+G%22">Chen G</searchLink>; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Pathology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Guan+Y%22">Guan Y</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Pan+LK%22">Pan LK</searchLink>; CCIC Group, Kuok Kim (Macao) Medical Center III, Macao, China.; Hui Xian Medical Center, Macao, China.<br /><searchLink fieldCode="AU" term="%22Xia+X%22">Xia X</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Guo+Z%22">Guo Z</searchLink>; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Pan+J%22">Pan J</searchLink>; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Xu+Y%22">Xu Y</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Yi+X%22">Yi X</searchLink>; Geneplus-Beijing, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Chen+C%22">Chen C</searchLink>; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2020 Aug 10; Vol. 11, pp. 1620. <i>Date of Electronic Publication: </i>2020 Aug 10 (<i>Print Publication: </i>2020).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32903763
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2020.01620
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1620
    Titles:
      – TitleFull: CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Huang Y
      – PersonEntity:
          Name:
            NameFull: Gao X
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Lin J
      – PersonEntity:
          Name:
            NameFull: Chen L
      – PersonEntity:
          Name:
            NameFull: Chang L
      – PersonEntity:
          Name:
            NameFull: Chen G
      – PersonEntity:
          Name:
            NameFull: Guan Y
      – PersonEntity:
          Name:
            NameFull: Pan LK
      – PersonEntity:
          Name:
            NameFull: Xia X
      – PersonEntity:
          Name:
            NameFull: Guo Z
      – PersonEntity:
          Name:
            NameFull: Pan J
      – PersonEntity:
          Name:
            NameFull: Xu Y
      – PersonEntity:
          Name:
            NameFull: Yi X
      – PersonEntity:
          Name:
            NameFull: Chen C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 08
              Text: 2020 Aug 10
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1